Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
EB EBS Emergent BioSolutions Inc. FY ended Feb 19, 2026 | $5.91 | $303.03M | $589.38M | $742.90M | $266.50M | $52.60M | 6.35x | 0.41x | 1.81x |
AZ AZN ASTRAZENECA PLC FY ended Dec 31, 2025 | — | — | — | $58.74B | $10.23B | $10.23B | — | — | — |
GS GSK GSK plc FY ended Dec 31, 2025 | $50.82 | $219.31B | $260.78B | $32.67B | $7.20B | $6.29B | 36.02x | 6.71x | 36.22x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 19.04x | 2/5 | $9.09B | $55.10 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 11.10x | 4/5 | $12.47B | $75.60 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 0.41x | 4/5 | $181.28M | $1.10 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
EB EBS Emergent BioSolutions Inc. FY ended Feb 19, 2026 | $5.91 | $303.03M | $589.38M | $742.90M | $266.50M | $52.60M | 6.35x | 0.41x | 1.81x |
AZ AZN ASTRAZENECA PLC FY ended Dec 31, 2025 | — | — | — | $58.74B | $10.23B | $10.23B | — | — | — |
GS GSK GSK plc FY ended Dec 31, 2025 | $50.82 | $219.31B | $260.78B | $32.67B | $7.20B | $6.29B | 36.02x | 6.71x | 36.22x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 19.04x | 2/5 | $9.09B | $55.10 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 11.10x | 4/5 | $12.47B | $75.60 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 0.41x | 4/5 | $181.28M | $1.10 | Included in the active peer mix. |
